Methodology
Notes.
12 Apr 2026
[PLACEHOLDER] On mechanism-class mapping in oncology deal flow
Why grouping deals by indication understates the structural shift toward antibody-drug conjugates and radioligand therapy — and what a cleaner taxonomy reveals.
8 min
03 Mar 2026
[PLACEHOLDER] Counterparty quality is not counterparty size
The conventional proxies for institutional quality — fund AUM, portfolio breadth, brand — collapse as predictors when the engagement is intuitu personae.
5 min
09 Feb 2026
[PLACEHOLDER] Why Swiss jurisdiction, and what it constrains
FINMA's perimeter is narrower than most foreign principals assume — but the constraints it does impose materially shape what a research practice can offer.
6 min